HeartBeam (NASDAQ:BEAT) Director Michael Jaff Buys 31,250 Shares

HeartBeam, Inc. (NASDAQ:BEAT) Director Michael Jaff purchased 31,250 shares of HeartBeam stock in a transaction dated Thursday, April 16th. The stock was acquired at an average price of $0.80 per share, for a total transaction of $25,000.00. Following the completion of the transaction, the director owned 31,250 shares in the company, valued at approximately $25,000. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

HeartBeam Stock Performance

NASDAQ BEAT opened at $0.81 on Friday. HeartBeam, Inc. has a one year low of $0.54 and a one year high of $4.00. The company has a 50-day simple moving average of $1.30 and a 200-day simple moving average of $1.62. The firm has a market capitalization of $33.28 million, a PE ratio of -1.31 and a beta of -0.63.

HeartBeam (NASDAQ:BEAT) last released its quarterly earnings data on Thursday, March 12th. The medical research company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01).

Analyst Ratings Changes

Several analysts recently issued reports on BEAT shares. Wall Street Zen downgraded HeartBeam to a “strong sell” rating in a report on Saturday, January 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $5.50 target price on shares of HeartBeam in a research report on Monday, March 16th. D. Boral Capital started coverage on HeartBeam in a research note on Friday, March 27th. They issued a “buy” rating and a $5.00 target price on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of HeartBeam in a report on Monday, December 29th. Finally, B. Riley Financial began coverage on shares of HeartBeam in a research report on Tuesday, March 31st. They set a “buy” rating and a $4.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $4.80.

More HeartBeam News

Here are the key news stories impacting HeartBeam this week:

• Positive Sentiment: Senior insiders (multiple directors and the CFO) purchased a total of ~1.12M shares at $0.80 apiece (roughly $895k in aggregate), including a 750k‑share buy by director Mark E. Strome, signaling management confidence and increasing insider ownership. SEC Filing — Mark E. Strome
• Positive Sentiment: Reported short interest fell ~22.8%, which reduces immediate short‑selling pressure and can support the share price during this post‑offering period. Short interest report
• Neutral Sentiment: Recent analyst/press comparison pieces examine HeartBeam versus peers; useful for longer‑term competitive/contextual perspective but not an immediate catalyst. Competitive comparison
• Negative Sentiment: HeartBeam launched and priced a $10 million public offering to support commercialization and AI initiatives. Equity offerings are dilutive and typically weigh on the share price; media coverage noted the stock slipped after the offering was priced. Offering pricing Offering closing Market reaction article

Institutional Investors Weigh In On HeartBeam

Hedge funds have recently made changes to their positions in the business. Clarity Financial LLC acquired a new position in shares of HeartBeam during the fourth quarter worth approximately $25,000. Bessemer Group Inc. bought a new stake in HeartBeam during the 3rd quarter valued at $25,000. CIBC Private Wealth Group LLC bought a new stake in HeartBeam during the 4th quarter valued at $26,000. Raymond James Financial Inc. boosted its position in HeartBeam by 102.2% during the 2nd quarter. Raymond James Financial Inc. now owns 28,178 shares of the medical research company’s stock worth $35,000 after acquiring an additional 14,242 shares during the period. Finally, Truist Financial Corp bought a new position in shares of HeartBeam in the fourth quarter worth $36,000. Institutional investors own 7.77% of the company’s stock.

About HeartBeam

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors.